A few weeks after the meeting, its head of API manufacturing, TL Easwar, left the company, two people with direct knowledge of the matter t...

Ranbaxy Laboratories said Tuesday it was suspending shipments from two of its plants following US import bans on its products over safety c...

Reacting to the news, shares of the drug maker plunged as much as 2.3 per cent in trade on the BSE, but recouped early morning losses quick...

The USFDA prohibited Ranbaxy Labs from manufacturing and distributing APIs from its Toansa plant for FDA-regulated drug products.

Rejecting sabotage theory at Toansa plant that faces USFDA ban, Ranbaxy denied blaming company's voluntary retirement scheme for problems i...

Analysts have maintained their cautious stance on Ranbaxy Laboratories even though the drugmaker reported a drastic drop in net loss.

Ranbaxy Laboratories has set aside Rs 257.4 crore towards the financial impact of a US ban on import of products made at its plant at Toans...

Ranbaxy Laboratories, the troubled drugmaker, has hinted at the possibility of sabotage by disgruntled employees at its manufacturing facil...

India’s drug regulator has ordered Ranbaxy to furnish a comprehensive explanation for the violation of manufacturing practices at its Toans...

Days after US FDA banned import of Ranbaxy products to America from its Toansa plant, health regulators of EU & UK have said they are evalu...

Other lapses included usage of un-calibrated and unqualified instruments in laboratory, said the report, which was released two days ago.

Toansa is the key active pharmaceutical ingredients facility and an alert is likely to put further pressure on business at least in the sho...

The USFDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa in Punjab.

Ranbaxy Laboratories Ltd plunged as much as 19.90 per cent in trade on Friday, after the US Food and Drug Administration import alert.

Terming the USFDA ban on its Toansa plant 'disappointing', Ranbaxy Laboaratories today said it will take 'appropriate management action' fo...

Ranbaxy Labs plunged as much as 19.69% , after the USFDA ban effectively stops the company from shipping drugs from its Toansa plant.

The Toansa plant is crucial for the company as about 70 per cent of APIs used in its formulations are said to be manufactured there.